Skip to main content
SpringerLink
Log in

Pathway Targeting, Antimycobacterial Drug Design

  • Reference work entry
Encyclopedia of Systems Biology

  • 82 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 899.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544

    PubMed  CAS  Google Scholar 

  • Ducati RG, Basso LA, Santos DS (2007) Mycobacterial shikimate pathway enzymes as targets for drug design. Curr Drug Targets 8:423–435

    PubMed  CAS  Google Scholar 

  • Kim TY, Kim HU, Lee SY (2010) Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. Metab Eng 12:105–111

    PubMed  CAS  Google Scholar 

  • Kumar A, Toledo JC, Patel RP, Lancaster JR Jr, Steyn AJ (2007) Mycobacterium tuberculosis DosS is a redox sensor and DosT is a hypoxia sensor. Proc Natl Acad Sci USA 104:11568–11573

    PubMed  CAS  Google Scholar 

  • Majumdar SD, Sharma D, Vashist A, Kaur K, Taneja NK, Chauhan S et al (2010) Co-expression of DevR and DevR(N)-Aph proteins is associated with hypoxic adaptation defect and virulence attenuation of Mycobacterium tuberculosis. PLoS One 5:e9448

    PubMed  Google Scholar 

  • Murphy DJ, Brown JR (2008) Novel drug target strategies against Mycobacterium tuberculosis. Curr Opin Microbiol 11:422–427

    PubMed  CAS  Google Scholar 

  • Parida BK, Douglas T, Nino C, Dhandayuthapani S (2005) Interactions of anti-sigma factor antagonists of Mycobacterium tuberculosis in the yeast two-hybrid system. Tuberculosis (Edinb) 85:347–355

    CAS  Google Scholar 

  • Raman K, Vashisht R, Chandra N (2009) Strategies for efficient disruption of metabolism in Mycobacterium tuberculosis from network analysis. Mol Biosyst 5:1740–1751

    PubMed  CAS  Google Scholar 

  • Rodrigue S, Provvedi R, Jacques PE, Gaudreau L, Manganelli R (2006) The σ factors of Mycobacterium tuberculosis. FEMS Microbiol Rev 30:926–941

    PubMed  CAS  Google Scholar 

  • Sachdeva P, Misra R, Tyagi AK, Singh Y (2010) The sigma factors of Mycobacterium tuberculosis: regulation of the regulators. FEBS J 277:605–626

    PubMed  CAS  Google Scholar 

  • Schreiber M, Res I, Matter A (2009) Protein kinases as antibacterial targets. Curr Opin Cell Biol 21:325–330

    PubMed  CAS  Google Scholar 

  • Spigelman MK (2007) New tuberculosis therapeutics: a growing pipeline. J Infect Dis 196(Suppl 1):S28–S34

    PubMed  Google Scholar 

  • Timm J, Post FA, Bekker LG, Walther GB, Wainwright HC, Manganelli R et al (2003) Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci USA 100:14321–14326

    PubMed  CAS  Google Scholar 

  • Tyagi JS, Sharma D (2004) Signal transduction systems of mycobacteria with special reference to M. tuberculosis. Curr Sci 86:93–102

    Google Scholar 

  • Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198:705–713

    PubMed  CAS  Google Scholar 

  • Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55:139–163

    PubMed  CAS  Google Scholar 

  • Williams KJ, Duncan K (2007) Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr Mol Med 7:297–307

    PubMed  CAS  Google Scholar 

  • Zhang Y (2005) The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 45:529–564

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Translational Health Science and Technology Institute, Gurgaon, 122016, India

    Dr. Deepak Sharma

  2. Molecular Biophysics Unit, Indian Institute of Science, Bangalore, 560012, India

    Dr. Avadhesha Surolia

Authors
  1. Dr. Deepak Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Avadhesha Surolia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepak Sharma .

Editor information

Editors and Affiliations

  1. Biomedical Sciences Research Institute, University of Ulster, Coleraine, UK

    Werner Dubitzky

  2. Department of Computer Science, University of Rostock, Rostock, Germany

    Olaf Wolkenhauer

  3. Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea

    Kwang-Hyun Cho

  4. Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY, USA

    Hiroki Yokota

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this entry

Cite this entry

Sharma, D., Surolia, A. (2013). Pathway Targeting, Antimycobacterial Drug Design. In: Dubitzky, W., Wolkenhauer, O., Cho, KH., Yokota, H. (eds) Encyclopedia of Systems Biology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9863-7_568

Download citation

Publish with us

Policies and ethics

Search

Navigation